<div class="modal hidden">
    <button class="close-btn">
        <i class="fas fa-times"></i>
    </button>
    <h4>TOFACITINIB TARGETS WHICH COMBINATION OF JAKS?</h4>
    <div class="btn-container">
        <button class="modal-btn">
            JAK1/JAK2 AND JAK1/JAK3
        </button>
        <button class="modal-btn">
            JAK1/JAK2, JAK1/JAK3, AND JAK2/JAK2
        </button>
        <button class="modal-btn">
            JAK2/JAK2 JAK1 AND JAK1 JJAK2AK1/JAK3
        </button>
        <button class="modal-btn">
            JAK1/JAK2 AND JAK2/JAK2
        </button>
        <div class="result hidden">
            <i class="fas fa-check"></i>
            CORRECT!
        </div>
        <button class="submit">
            <i class="fas fa-check"></i>
            SUBMIT
        </button>
    </div>
</div>
<section id="ct" class="section">
    <nav class="desktop">
        <a href="" ui-sref="MOA" class="moa">
            <i class="fas fa-atom"></i>
        </a>
        <a href="" ui-sref="CT" class="ct active">
            <i class="fas fa-users"></i>
        </a>
        <a href="" ui-sref="EFFICACY" class="efficacy">
            <i class="fas fa-chart-line"></i>
        </a>
        <a href="" ui-sref="SAFETY" class="safety">
            <i class="fas fa-exclamation-triangle"></i>
        </a>
        <a href="" ui-sref="DOSING" class="dosing">
            <i class="fas fa-prescription"></i>
        </a>
    </nav>
    <main>
    <div class="top">
        <a href="" ui-sref="LANDING-PAGE"><img src="assets/pfizer-logo.svg" alt="Pfizer Logo"></a>
        <h1>Tofacitinib pcJIA</h1>
    </div>
    <div class="content swiper mySwiper">
        <div class="swiper-wrapper">
            <div class="swiper-slide">
                <h3 class="ct-header">STUDY DESIGN</h3>
                <div class="content-container">

                <div class="slide-btns">
                    <a href="" ui-sref="DOSAGE-REGIMEN" class="slide-btn">DOSAGE REGIMEN</a>
                    <a href="" ui-sref="STATISTICAL-ANALYSIS" class="slide-btn">STATISTICAL ANALYSIS</a>
                    <a href="" ui-sref="PATIENT-DISPOSITION" class="slide-btn">PATIENT DISPOSITION</a>
                    <a href="" ui-sref="JIA-CATEGORIES" class="slide-btn">JIA CATEGORIES</a>
                </div>
                <h4>International, randomized, double-blind, placebo-controlled withdrawal study</h4>
                <div class="img-wrapper">
                <img src="assets/ct/study-design.png" class="ct-1" alt="study-design" />
                </div>
                <div class="tables">
                    <div class="table">
                        <h5>Key inclusion criteria</h5>
                        <ul>
                            <li>Age 2-&lt;18 years</li>
                            <li>Active pcJIA, jPsA, or ERA
                                <ul>
                                    <li>&geq;5 active joints in pcJIA</li>
                                    <li>&geq;3 active joints in jPsA or ERA</li>
                                </ul>
                            </li>
                            <li>Inadequate response or intolerance to &geq;1 DMARD</li>
                            <li>Systemic patients without systemic features for 6 months</li>
                        </ul>
                    </div>
                    <div class="table">
                        <h5>Key exclusion criteria</h5>
                        <ul>
                            <li>Systemic JIA with active systemic features</li>
                            <li>Persistent oligoarthritis</li>
                            <li>Undifferentiated JIA</li>
                            <li>Active uveitis</li>
                        </ul>
                    </div>
                </div>
                </div>
                <div class="footnotes">
                    <ol>
                        <li>Dosed at either 5 mg tablet or equivalent body weight equivalent BID with oral solution;</li>
                        <li>Patients in any arm could be on NSAIDS, methotrexate, or corticosteroids.</li>
                        <li>173 patients were randomized to DB period. ACR30 =&geq;30% improvement in American College of Rheumatology score</li>
                    </ol>
                    <p>ACR=acute phase reactant; BID=twice daily. DMARD=disease-modifying antirheumatic drug; ERA=enthesitis-related arthritis; JIA=juvenile idiopathic arthritis; jPsA=juvenile psoriatic arthritis; pcJIA=polyarticular-course juvenile idiopathic arthritis.</p>
                    <p>Data on file. Pfizer Inc., New York, NY. 2022</p>
                </div>
            </div>
            <div class="swiper-slide endpoints">
                <div class="content-container">
                <h3 class="ct-header">ENDPOINTS</h3>
                <h4 class="endpoint-header">PRIMARY ENDPOINT</h4>
                <ul class="check">
                    <li>Occurrence of disease flare a at Wk 44 in DB phase (Weeks 18-44)</li>
                </ul>
                <h4 class="endpoint-header lighter">KEY SECONDARY ENDPOINTS</h4>
                <ul class="check">
                    <li>JIA ACR30/50/70 response b rates at Week 44 (vs Part 1 baseline)</li>
                    <li>Change from DB phase baseline in CHAQ DI at Week 44</li>
                </ul>
                <h4 class="endpoint-header lighter">OTHER SELECT SECONDARY ENDPOINTS</h4>
                <ul class="check">
                    <li>Time to disease flare in DB phase</li>
                    <li>JIA ACR30/50/70 response b rates over time in Part 1 (18 Wks)</li>
                    <li>Mean JADAS27 CRP over time in Part 1 and Part 2</li>
                </ul>
                <hr>
                <ul class="check">
                    <li class="bold">Reported in patients with pcJIA</li>
                    <li>Efficacy in patients with jPsA and ERA assessed separately</li>
                </ul>
            </div>
            <div class="footnotes">
                <ol>
                    <li>Flare is defined as a worsening of &geq;30% in &geq;3 of the 6 variables of the JIA core set, with &leq;1 variable improving by &geq;30%</li>
                    <li>Flare is defined as a worsening of &geq;30% in &geq;3 of the 6 variables of the JIA core set, with &leq;1 variable improving by &geq;30%</li>
                </ol>
                <p>DB, double blind; CHAQ-DI, Childhood Health Assessment Questionnaire Disability Index; JADAS27 CRP, Juvenile Arthritis Disease Activity Score based on C reactive protein.
                </p>
                <p>Ruperto N. <span class="italic">Lancet</span>. 2021;398:1984-1996.</p>
            </div>
            </div>
            <div class="swiper-slide secondary-endpoints">
                <h3 class="ct-header">SECONDARY SAFETY ENDPOINTS</h3>
                <div class="content-container">
                <hr>
                <h4>Evaluated throughout study in all patients (pcJIA /jPsA/ERA)</h4>
                <ul class="check">
                    <li>AEs, SAEs, discontinuations due to AEs, and temporary dose reductions or discontinuations due to AEs</li>
                    <li>AEs of special interest<sup>*</sup>:</li>
                    <ul class="bullet">
                        <li>Death</li>
                        <li>Gastrointestinal perforation</li>
                        <li>Hepatic events</li>
                        <li>Herpes zoster</li>
                        <li>Interstitial lung disease</li>
                        <li>Major adverse cardiovascular events</li>
                        <li>Malignancies (including NMSC)</li>
                        <li>Macrophage activcation syndrome</li>
                        <li>Opportunistic infections</li>
                        <li>Serious infections</li>
                        <li>Thrombotic events<sup>â€ </sup></li>
                        <li>Tuberculosis</li>
                    </ul>
                    <li>Laboratory abnormalities</li>
                    <li>Assessments of growth and pubertal development (Tanner Stage of Development)</li>
                </ul>
                </div>
                <div class="footnotes">
                    <p><sup>*</sup>AEs of special interest were not prespecified.</p> <ol><li>DVT, PE, or ATE</li></ol>
                    <p>AE, adverse event; ATE, arterial thromboembolism; DVT, deep vein thrombosis; ERA, enthesitis-related arthritis; jPsA, juvenile psoriatic arthritis; NMSC, non melanoma skin cancer; pcJIA, polyarticular course juvenile idiopathic arthritis; PE, pulmonary embolism; SAE, serious adverse event.</p>
                    <p>Ruperto N. <span class="italic">Lancet</span>. 2021;398:1984-1996.</p>
                </div>
            </div>
            <div class="swiper-slide patient-demographics">
                <h3 class="ct-header">PATIENT DEMOGRAPHICS</h3>
                <div class="content-container">
                <div class="slide-btns">
                    <a href="" ui-sref="BASELINE-DISEASE-CHARACTERISTICS" class="slide-btn">BASELINE DISEASE CHARACTERISTICS</a>
                </div>
                <div class="img-wrapper">
                    <img src="assets/ct/patient-demographics.png" alt="patient demographics" />
                </div>
                </div>
                <div class="footnotes">
                    <ol>
                        <li>5 mg BID or equivalent weight-based lower dose in patients &lt;40 kg.</li>
                        <li>Europe includes Belgium, Great Britain, Poland, and Spain.</li>
                        <li>All other includes Australia, Israel, Russia, Turkey, and Ukraine.</li>
                    </ol>
                    <p>
                        Data presented for patients with pcJIA , jPsA, or ERA;  Q1, 25th percentile; Q3, 75th percentile.
                    </p>
                    <p>OL, open label; BID, twice daily; DB, double blind; ERA, enthesitis-related arthritis; jPsA, juvenile psoriatic arthritis; PBO, placebo; pcJIA, polyarticular course juvenile idiopathic arthritis.</p>
                    <p>Data on file. Pfizer Inc. 2022.</p>
                </div>
            </div>
            <div class="swiper-slide phase-pk-analysis">
                <h3 class="ct-header">PHASE 1 PK ANALYSIS</h3>
                <div class="content-container">
                <div class="slide-btns">
                    <a href="" ui-sref="TRIAL-DESIGN" class="slide-btn">TRIAL DESIGN</a>
                    <a href="" ui-sref="PLASMA-CONCENTRATIONS" class="slide-btn">PLASMA CONCENTRATIONS</a>
                </div>
                <h5 class="light">Plasma tofacitinib pharmacokinetic parameter values by cohort</h5>
                <div class="img-wrapper">
                    <img src="assets/ct/phase-pk-analysis.png" alt="Phase 1 PK Analysis" />
                </div>
                </div>
                <div class="footnotes">
                    <p>pcJIA, polyarticular course juvenile idiopathic arthritis; PK, pharmacokinetics.</p>
                    <p>Ruperto N. <span class="italic">Lancet</span>. 2021;398:1984-1996.</p>
                </div>
            </div>
        </div>
        <div class="swiper-button-next ct">
            NEXT
        </div>
        <div class="swiper-button-prev ct">PREVIOUS</div>
        <div class="swiper-pagination ct"></div>
        </div>
        <button class="review-btn ct vis-hidden">
            <i class="fas fa-question"></i>
            <h5>REVIEW</h5>
        </button>
    </main>
</div>
    <nav class="mobile">
        <a href="" class="moa">
            <i class="fas fa-atom"></i>
            <h5>MOA</h5>
        </a>
        <a href="" class="ct active">
            <i class="fas fa-users"></i>
            <h5>Clinical Trials</h5>
        </a>
        <a href="" class="efficacy">
            <i class="fas fa-chart-line"></i>
            <h5>Efficacy</h5>
        </a>
        <a href="" class="safety">
            <i class="fas fa-exclamation-triangle"></i>
            <h5>Safety</h5>
        </a>
        <a href="" class="dosing">
            <i class="fas fa-prescription"></i>
            <h5>Dosing</h5>
        </a>
    </nav>
</section>
<script src="js/ct/swiper-config.js" defer></script>